hexenoyl group comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
| Property | Value | Notes |
|---|---|---|
| Drug class | Peptide hormone analog | Acts at the growth hormone-releasing hormone receptor |
| Receptor | Growth hormone-releasing hormone receptor | G protein-coupled; raises cyclic AMP in somatotrophs |
| Key mediator | Insulin-like growth factor 1 | Increases with repeated administration |
| Main studied population | Adults with HIV-associated lipodystrophy | Trials measured visceral adipose tissue by imaging |
| Route | Subcutaneous injection | Given once daily in clinical use |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
=== Protein–protein interactions === (Yeast) two-hybrid system Protein-fragment complementation assay Co-immunoprecipitation Affinity purification and mass spectrometry Proximity ligation assay Proximity labeling
=== Normal values === Reference ranges for blood tests of plasma renin activity can be given both in mass and in international units (μIU/mL or equivalently mIU/L, improperly shown as μU/mL or U/L, confusing mcU/mL used where Greek μ not available), with the former being roughly convertible to the latter by multiplying with 11.2. The following table gives the lower limit (2.5th percentile) and upper limit (97.5th percentile) for plasma renin activity by mass and MCU, with different values owing to various factors of variability of reference ranges:
In 1941, at age 40, Pauling was diagnosed with Bright's disease, a renal disease. Following the recommendations of Thomas Addis, who actively recruited Ava Helen Pauling as "nutritionist, cook, and eventually as deputy 'doctor'", Pauling believed he was able to control the disease with Addis's then-unusual low-protein salt-free diet and vitamin supplements. Thus Pauling's initial – and intensely personal – exposure to the idea of treating disease with vitamin supplements was positive. In 1965, Pauling read Niacin Therapy in Psychiatry by Abram Hoffer and theorized vitamins might have important biochemical effects unrelated to their prevention of associated deficiency diseases. In 1968, Pauling published a brief paper in Science entitled "Orthomolecular psychiatry", giving a name to the popular but controversial megavitamin therapy movement of the 1970s, and advocating that "orthomolecular therapy, the provision for the individual person of the optimum concentrations of important normal constituents of the brain, may be the preferred treatment for many mentally ill patients." Pauling coined the term "orthomolecular" to refer to the practice of varying the concentration of substances normally present in the body to prevent and treat disease. His ideas formed the basis of orthomolecular medicine, which is not generally practiced by conventional medical professionals and has been strongly criticized. In 1973, with Arthur B.
The first stores opened in the end of 2016 in the Cape Town area. Eventually, only 11 Dunkin' Donuts locations and five Baskin-Robbins locations opened in South Africa due to GPI's financial trouble. However, by February 2019, Grand Parade Investments announced that it permanently closed all Dunkin' Brands locations in South Africa due to poor performance. In September 2015, Roland Zanelli, the owner of the Dunkin' Donuts license in Switzerland, announced the opening of the first two stores in Basel, Switzerland in Fall 2015, followed by the opening of up to 60 stores in the whole country. The first Basel store opened on March 1, 2016. In 2024, the company's operations in Belgium and the Netherlands went bankrupt, but insisted that all of the locations would stay open.
Sources: en.wikipedia.org
(1914–2006), American physicist and chemist who won the 2002 Nobel Prize in Physics for detecting neutrinos emitted from the Sun Humphry Davy (1778–1829), British chemist, discovered several alkaline earth metals Serena DeBeer (born 1973), American chemist known for developing X-ray based spectroscopic probes of electronic structure Peter Debye (1884–1966), Dutch chemist who improved the theory of electrical conductivity in electrolyte solutions, winner of the 1936 Nobel Prize in Chemistry Johann Deisenhofer (born 1943), German biochemist who determined the three-dimensional structure of a protein complex found in photosynthetic bacteria, 1988 Nobel Prize in Chemistry Margarita del Val (born 1959), Spanish chemist, immunologist, and virologist, coordinator of the Salud Global ("Global Health") platform Nathalie Demassieux (1884–1961), French mineral chemist and academic who worked on the complex halogenated salts of lead Gautam Radhakrishna Desiraju (born 1952), Indian chemist known for work on crystal engineering and weak hydrogen bonds James Dewar (1842–1923), British chemist and physicist known for his invention of the vacuum flask and its usefor studying the liquefaction of gases François Diederich (1952–2020), Luxembourg chemist known for molecular recognition studies with biological receptors Otto Diels (1876–1954), German chemist, winner of the 1950 Nobel Prize in Chemistry for the Diels–Alder reaction, a method for cyclohexene synthesis Robert Dirks (1978–2015), American computational chemist known for work on DNA nanotechnology
Several modern western scholars argue that there are inconsistencies in the list of twelve links, and regard it to be a later synthesis of several older lists and elements, some of which can be traced to the Vedas. The doctrine of dependent origination appears throughout the early Buddhist texts. It is the main topic of the Nidāna Saṃyutta of the Theravada school's Saṃyutta Nikāya (henceforth SN). A parallel collection of discourses also exists in the Chinese Saṁyukta Āgama (henceforth SA).
===== MHCI presentation ===== In the simplified view of this pathway HSPs are usually not mentioned: antigenic peptides are generated in proteasome, transported into ER through protein transporter TAP and loaded onto MHCI, which then goes through secretory pathway on plasma membrane. But HSPs play an important part in transfer of unfolded proteins to proteasome and generated peptides to MHCI. Hsp90 can associate with proteasome and take over generated peptides. Afterwards, it can associate with hsp70, which can take the peptide further to the TAP. After passing through TAP, ER chaperons are getting important - calreticulin binds peptides and together with gp96 form peptide loading complex for MHCI. This handing over with peptides is important, because HSPs can shield hydrophobic residues in peptides which would be otherwise problematic in aquatic cytosol. Also simple diffusion of peptides would be too ineffective.
On 4 April, explosions were reported at an auxiliary building of the Bushehr Nuclear Power Plant as well as the Mahshahr Special Petrochemical Zone in Mahshahr, Iran. The airstrikes in Mahshahr killed at least five and injured 170 others. An Iranian missile strike hit in the vicinity of the IDF's HaKirya headquarters in Tel Aviv. On 5 April, after heavy fighting, the second stranded crew member from the F-15E downed on 3 April was recovered by US forces in a rescue operation, which resulted in damage to helicopters, the shooting down of an A-10 Thunderbolt II, and the destruction of two C-130 Hercules, three IRGC members killed, and several American service members injured. On 6 April, the IRGC announced that the head of the IRGC's intelligence organization, Major General Majid Khademi, had been killed in a joint US-Israeli airstrike. Their statement claimed that Khademi had "played a major role in Iran's intelligence and security apparatus over nearly five decades". Israel said that Yazdan Mir, a high-ranking commander of the IRGC Quds Force, had also been killed in the attacks. On the same day, before Trump's deadline for targeting Iranian infrastructure, Israel carried out strikes on the South Pars Petrochemical facility in Asaluyeh, Iran. The IAF said that "85% of Iran's petrochemical exports" had been taken offline by now. At least 34 people, including six children, were killed in US-Israeli airstrikes across Iran, including against Sharif University of Technology and residential areas.
Rearing a relatively small number of grazing animals can be beneficial, as the Food Climate Research Network at Surrey University reports: "A little bit of livestock production is probably a good thing for the environment". In May 2009, Ghent, Belgium, was reported to be "the first [city] in the world to go vegetarian at least once a week" for environmental reasons, when local authorities decided to implement a "weekly meatless day". Civil servants would eat vegetarian meals one day per week, in recognition of the United Nations' report. Posters were put up by local authorities to encourage the population to take part on vegetarian days, and "veggie street maps" were printed to highlight vegetarian restaurants. In September 2009, schools in Ghent are due to have a weekly veggiedag ("vegetarian day") too. Public opinion and acceptance of meat-free food is expected to be more successful if its descriptive words focus less on the health aspects and more on the flavor.
Sources: en.wikipedia.org
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.
Administered growth hormone supplies the hormone directly, while this peptide acts upstream by prompting the pituitary to release it. The indirect route preserves pulsatile secretion and some endogenous feedback, which changes the hormone and IGF-1 profile observed after treatment.
Reductions in visceral adipose tissue appear consistently in randomized trials of the approved population. Effects on peripheral fat, cardiovascular outcomes, and use outside that population are less well established.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.